| abstract |
The present invention provides compounds, pharmaceutical compositions thereof, and their use as IDH1 mutation inhibitors for the treatment of cancer. A compound of formula (I) is provided wherein X, Y, Z, W, V, R2, R3 and m are defined as described herein. Also provided are their pharmaceutical compositions and their use as IDH1 mutation inhibitors for cancer treatment. The compounds of formula I inhibit mutant IDH1, in particular mutant IDH1 having alpha hydroxyl new activity. Also described herein are pharmaceutical compositions comprising a compound of formula I and methods of using such compositions to treat cancer characterized by the presence of mutant IDH1. [Selection figure] None |